Sign In
Buy ABBV
$224.93
+7.86 (+3.62%)
At Close: Jun 04, 2026
Big Pharma Stocks Dive Amid Trade War Jitters & Inflation Woes
09:40am, Monday, 07'th Apr 2025
Shares of pharma giants like PFE, J&J, AZN, MRK and ABBV decline on investor concerns that retaliatory tariffs could drive up drug prices for U.S. consumers.
3 Dividend Stocks to Buy and Hold for the Next Decade
06:44am, Sunday, 06'th Apr 2025
What should investors do when stocks are tanking over the short term? Probably the best answer is to think long term.
2 Dividend Stocks to Buy Hand Over Fist in April
08:30am, Saturday, 05'th Apr 2025
One factor that keeps some investors away from healthcare stocks is the sector's dearth of generous and reliable dividend payers. This stands to reason, as nearly every stage of drug development and m
4 Blue Chip Pharmaceutical High-Yield Dividend Stocks Are Tariff Winners
04:44pm, Friday, 04'th Apr 2025
With some pharmaceutical stocks paying 4% and higher dividends, they may be the perfect total return idea for the rest of 2025.
AbbVie cuts 2025 profit forecast on acquisition expenses
04:35pm, Thursday, 03'rd Apr 2025
AbbVie on Thursday cut its 2025 adjusted profit forecast as the drugmaker expects to incur $248 million in acquisition-related expenses.
3 High-Yielding Dividend Stocks That Retirees Can Buy and Forget About
09:00am, Thursday, 03'rd Apr 2025
"Buy and hold" is a simple strategy for investors, but it can be a hard one to stick to in actual practice. That's because many people want to pick stocks and trade them, and feel like they need to ac
AbbVie Stock Rises 16% Year to Date: Time to Buy, Sell or Hold?
11:10am, Wednesday, 02'nd Apr 2025
Those who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth in 2025.
Trump's tariffs are a new challenge for Big Pharma. Here are the best positioned stocks
02:01pm, Tuesday, 01'st Apr 2025
Leerink Partners analyst David Resinger warned his clients on Sunday that the tariff risks to the industry are 'underappreciated.'
Best Dividend Aristocrats For April 2025
04:07pm, Monday, 31'st Mar 2025
Dividend Aristocrats are outperforming the S&P 500 in 2025, demonstrating resilience, with NOBL up 1.78% YTD versus SPY's 4.9% decline. Top performers include Consolidated Edison (+22.98%), Brown & Br
AbbVie: Margin Expansion Potential Can Support Elevated P/E
10:20am, Monday, 31'st Mar 2025
I don't see an obvious bias in AbbVie Inc.'s risk/return ratio. But I see it as a solid hold under current conditions. The company is grappling with diminishing Humira sales and is also trading at an
AbbVie to Host First-Quarter 2025 Earnings Conference Call
08:00am, Monday, 31'st Mar 2025
NORTH CHICAGO, Ill. , March 31, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its first-quarter 2025 financial results on Friday, April 25, 2025, before the market opens.
Want $1 Million in Retirement? 3 Stocks to Buy Now and Hold for Decades.
04:53am, Monday, 31'st Mar 2025
Building a retirement portfolio of $1 million or more is within reach for many Americans. The primary things you'll need are time and money to invest.
Top 4 defensive stocks to buy and hold ahead of Liberation Day
02:32pm, Saturday, 29'th Mar 2025
American stocks have crashed this year as concerns about Donald Trump tariffs rose. The top blue-chip indices like the Dow Jones, Nasdaq 100, and S&P 500 have all moved into a correction as recession
3 Relatively Safe Stocks to Buy Right Now
06:45am, Saturday, 29'th Mar 2025
Investing in stocks comes with risks. There's no way around that fact.
Regulatory Condition Satisfied for License Agreement between AbbVie and Gubra
06:20pm, Friday, 28'th Mar 2025
HØRSHOLM, DK / ACCESS Newswire / March 28, 2025 / Gubra (CPH:GUBRA) With reference to AbbVie's (NYSE:ABBV) and Gubra A/S' (CPSE:GUBRA) joint announcement of March 3, 2025 regarding a license agreemen
